Skip to main content
HOWL
NASDAQ Life Sciences

MPM BioVentures Group Continues Selling Shares, Reduces Stake in Werewolf Therapeutics

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.6
Mkt Cap
$30.713M
52W Low
$0.53
52W High
$2.38
52W Position info
13% above low
Off High info
75% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

HOWL is trading near its 52-week low of $0.53 (13% above the low).

Summary

A group of institutional investors led by MPM BioVentures continued to sell shares of Werewolf Therapeutics, disposing of approximately $530,000 worth of stock and further reducing their stake as the company navigates significant financial challenges.


Key Events · Ownership and Investor Activity · HOWL

  • Continued Institutional Selling

    MPM BioVentures and associated entities sold approximately $530,000 worth of common stock in open market transactions between May 6 and May 12, 2026.

  • Reduced Beneficial Ownership

    The sales further reduced the group's stake, with Ansbert Gadicke now holding 3.8%, Luke Evnin 2.4%, and Todd Foley 1.8% of the outstanding shares.

  • Ongoing De-risking Strategy

    This distribution follows a pattern of institutional investors reducing exposure to the company, which is exploring strategic alternatives and faces 'going concern' doubts.


Analysis · HOWL · Life Sciences

This Schedule 13D/A reports that the MPM BioVentures group, including associated individuals, sold approximately $530,000 worth of Werewolf Therapeutics common stock in open market transactions between May 6 and May 12, 2026. These sales represent a continued reduction in their beneficial ownership, with key individuals like Ansbert Gadicke, Luke Evnin, and Todd Foley now holding 3.8%, 2.4%, and 1.8% respectively. This ongoing distribution by a major institutional investor group signals a continued de-risking strategy amidst the company's previously disclosed workforce reduction, exploration of strategic alternatives, and "going concern" doubts, despite a recent asset sale and debt repayment.

At the time of this filing, HOWL was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.7M. The 52-week trading range was $0.53 to $2.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HOWL - Latest Insights

HOWL
Jul 31, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.490
Real-time Price: $0.4019 info
Change: -$0.0881 (-18%) info
Market Cap: $19.532M info
HOWL
Jul 31, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.490
Real-time Price: $0.4019 info
Change: -$0.0881 (-18%) info
Market Cap: $19.532M info
HOWL
Jul 06, 2026, 5:18 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $0.315
Real-time Price: $0.4019 info
Change: +$0.0869 (+28%) info
Market Cap: $19.532M info
HOWL
Jul 02, 2026, 8:26 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.330
Real-time Price: $0.4019 info
Change: +$0.0719 (+22%) info
Market Cap: $19.532M info
HOWL
Jun 26, 2026, 5:39 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.323
Real-time Price: $0.4019 info
Change: +$0.0789 (+24%) info
Market Cap: $19.532M info